Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

Icosabutate and FFAR1/FFAR4 Agonism in Metabolic Dysfunction-Associated Steatohepatitis (MASH): Insights from the ICONA Phase IIb Trial

The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and diabetic populations.
Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Dose-Dependent Enhancement of L-Tryptophan-Induced Gut Hormone Secretion and Appetite Suppression by Intraduodenal Calcium in Obesity

Intraduodenal calcium at doses up to 1000 mg amplifies the anorexigenic effects of L-tryptophan by boosting gut hormones CCK, GLP-1, and PYY, reducing energy intake in obese males, highlighting a novel adjunctive approach for appetite regulation in obesity management.
Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial

Optimizing Colorectal Cancer Screening Outreach for Adults Aged 45-49: Insights From a Large-Scale Randomized Trial

A large UCLA Health randomized clinical trial found that usual care via mailed FIT outreach outperformed active choice strategies in colorectal cancer screening uptake among adults aged 45 to 49 years, highlighting the challenges in engaging younger populations in screening programs.
Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

Parecoxib and Imrecoxib Sequential Therapy: A Breakthrough in Managing Severe Acute Pancreatitis

This multicentre trial shows sequential use of COX-2 inhibitors parecoxib and imrecoxib significantly reduces severe acute pancreatitis (SAP) incidence, shortens organ failure duration, lowers local complications, and decreases 30-day mortality, with a good safety profile.